Dados de segurança do asundexiana, um novo anticoagulante oral direto para fibrilação atrial

Referência

1. Dr. Manesh R. Patel et al., Multicenter, Randomized, Active Comparator-controlled, Double-blind, Double-dummy, Parallel Group, Dose-finding Phase 2 Study Comparing The Safety Of The Oral FXIa Inhibitor Asundexian With Apixaban In Patients With Atrial Fibrillation: PACIFIC AF. Presented at the American College of Cardiology Annual Scientific Session (ACC 2022), Washington, DC, April 2, 2022.